# Study of RP-3500, Camonsertib, in Advanced Solid Tumors

> **NCT04497116** · PHASE1,PHASE2 · COMPLETED · sponsor: **Repare Therapeutics** · enrollment: 276 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** RP-3500 (camonsertib)
- **DRUG:** Talazoparib
- **DRUG:** Gemcitabine Injection

## Key facts

- **NCT ID:** NCT04497116
- **Lead sponsor:** Repare Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-22
- **Primary completion:** 2025-06-13
- **Final completion:** 2025-06-13
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04497116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04497116, "Study of RP-3500, Camonsertib, in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04497116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*